"2 prizes for Incit at the Go Immuno congress - December 11 & 12, 2023".
INCIT in the spotlight at the "Go Immuno" conference organized by Labex IGO in December. In...
News :
Obtaining a 300 K€ funding from the Defense Innovation Agency (AID) via the ANR within the framework of the "Specific Support for Defense Research and Innovation" program (ASTRID)
Publication date: July 28, 2022
Read also:
read more
European funding for immunotherapy of inflammatory bowel diseases
HORIZON Europe Framework Program : coordinated by F. ALTARE INCIT joins the RAISE network...
"Cross-talks between Death Receptor signalling and ER stress response in cancer".
Seminar Speaker: Elodie Lafont (U1242 Inserm, Centre...
Read more articles
"2 prizes for Incit at the Go Immuno congress - December 11 & 12, 2023".
INCIT was honored at the "Go Immuno" conference organized by Labex IGO in December. Margaux Verdon (team 1) was awarded the prize for best poster, while Gwenann Cadiou (team 3) won the prize for best oral communication!
European funding for immunotherapy of inflammatory bowel diseases
The INCIT unit is pleased to announce that it has been awarded an ambitious European program on immunotherapy, bringing together 7 partners (including 2 biotechs) in 4 European countries. This program is coordinated by Frédéric ALTARE, Director of the UMR 1302, INCIT in Nantes. Project title: immunotherapy of inflammatory bowel diseases
"Cross-talks between Death Receptor signalling and ER stress response in cancer".
Dr Elodie Lafont (U1242 Inserm, Centre Eugène Marquis, Rennes), guest of Team 2, will give a seminar entitled: Cross-talks between Death Receptor signalling and ER stress response in cancer , on November 27 at 14.00 - Rooms 1, 2, 3 - IRS2, Nantes
"Reactivation of the STING pathway to improve the efficacy of immunotherapies (anti-PD(L)1) in heterotypic spheroid models of urothelial carcinoma."
Dr Céline Gongora (Institut de cancérologie de Montpellier (IRCM), guest of Team 3, will give a seminar entitled: Reactivation of the STING pathway to improve the efficacy of immunotherapies (anti-PD-(L)1) in urothelial carcinoma models , June 21 at 11.00 - Rooms 1, 2, 3 - IRS2, Nantes